Tag Archive: Accelerated Approval Program

Aug 29

FDA Approves First Drug Specifically Formulated to Treat Pediatric Tumors

On August 29, 2012, the U.S. Food and Drug Administration (“FDA”) announced the Agency’s approval of a new drug formulated specifically to treat children with a rare type of brain tumor, known as subependymal giant cell astrocytoma (SEGA). Manufactured by Novartis, Afinitor Disperz is a new dosage form of the existing anti-cancer drug Afinitor. While …

Continue reading »

Switch to our mobile site